Leukemias – Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 436 pages

Leukemias – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Leukemias - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Leukemias, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leukemias. Leukemias - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Leukemias.
- A review of the Leukemias products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Leukemias pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Leukemias.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Leukemias pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Leukemias - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Leukemias Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Leukemias 13
Leukemias Therapeutics under Development by Companies 15
Leukemias Therapeutics under Investigation by Universities/Institutes 23
Late Stage Products 26
Comparative Analysis 26
Mid Clinical Stage Products 27
Comparative Analysis 27
Early Clinical Stage Products 28
Comparative Analysis 28
Discovery and Pre-Clinical Stage Products 29
Comparative Analysis 29
Leukemias Therapeutics - Products under Development by Companies 30
Leukemias Therapeutics - Products under Investigation by Universities/Institutes 38
Companies Involved in Leukemias Therapeutics Development 40
Boehringer Ingelheim GmbH 40
Amgen Inc. 41
Eli Lilly and Company 42
Athersys, Inc. 43
GlaxoSmithKline plc 44
Seattle Genetics, Inc. 45
MedImmune LLC 46
Daiichi Sankyo Company, Ltd 47
Emergent BioSolutions Inc. 48
Gamida Cell Ltd. 49
BioLineRx, Ltd. 50
Amorfix Life Sciences Ltd. 51
Bio-Path Holdings, Inc. 52
ZIOPHARM Oncology, Inc. 53
Novartis AG 54
Aphios Corporation 55
CK Life Sciences Int'l., (Holdings) Inc. 56
Daewoong Pharmaceutical Co., Ltd. 57
Genta Incorporated 58
GTC Biotherapeutics, Inc. 59
Nippon Shinyaku Co., Ltd. 60
Ono Pharmaceutical Co., Ltd. 61
Pfizer Inc. 62
SuperGen, Inc. 63
Teva Pharmaceutical Industries Limited 64
Genmab A/S 65
Merck KGaA 66
Celldex Therapeutics, Inc. 67
Marshall Edwards, Inc. 68
MethylGene Inc 69
Northwest Biotherapeutics, Inc. 70
Telik, Inc. 71
Mundipharma International Limited 72
Pharmacyclics, Inc. 73
Cytomedix, Inc. 74
Array BioPharma Inc. 75
Threshold Pharmaceuticals, Inc. 76
CrystalGenomics, Inc. 77
Sareum Holdings plc 78
MetrioPharm AG 79
SymBio Pharmaceuticals Limited 80
Abiogen Pharma S.p.A. 81
Multimmune GmbH 82
Nerviano Medical Sciences S.r.l. 83
ViroStatics, srl 84
MAT Biopharma 85
Celator Pharmaceuticals, Inc. 86
Hawthorn Pharmaceuticals, Inc. 87
ACT Biotech, Inc. 88
Constellation Pharmaceuticals, Inc. 89
Deciphera Pharmaceuticals, LLC 90
MSM Protein Technologies, Inc. 91
Reata Pharmaceuticals, Inc. 92
Stemline Therapeutics, Inc. 93
Synageva BioPharma Corp. 94
MolMed S.p.A. 95
NOXXON Pharma AG 96
Morphogenesis, Inc. 97
SBI Biotech Co., Ltd. 98
Tragara Pharmaceuticals, Inc. 99
Cellceutix Corporation 100
PharmaMar, S.A. 101
Cylene Pharmaceuticals, Inc. 102
Lipopharma 103
Keystone Nano, Inc. 104
Toko Pharmaceutical Industries Co., Ltd. 105
Cancer Therapeutics CRC Pty Ltd 106
EpiZyme, Inc. 107
Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd. 108
iCeutica, Inc. 109
Polaris Group 110
XBiotech USA, Inc. 111
Wellstat Biologics Corporation 112
Immunovative Therapies, Ltd. 113
Advancell 114
Leukemias - Therapeutics Assessment 115
Assessment by Monotherapy Products 115
Assessment by Combination Products 116
Assessment by Route of Administration 117
Assessment by Molecule Type 119
Drug Profiles 122
StemEx - Drug Profile 122
alvocidib - Drug Profile 124
oblimersen sodium - Drug Profile 125
moxetumomab pasudotox - Drug Profile 128
brentuximab vedotin - Drug Profile 130
CDX-1127 - Drug Profile 134
acadesine - Drug Profile 135
MultiStem - Drug Profile 137
mocetinostat - Drug Profile 140
ibrutinib - Drug Profile 143
ENKASTIM-ev - Drug Profile 146
mi-APO - Drug Profile 147
AT-9283 - Drug Profile 148
ALD-151 - Drug Profile 150
IMD-5 - Drug Profile 151
bafetinib - Drug Profile 152
cilengitide - Drug Profile 154
TRU-016 - Drug Profile 157
pracinostat - Drug Profile 159
TG-02 - Drug Profile 161
ARRY-520 - Drug Profile 163
forodesine hydrochloride - Drug Profile 165
CXCR4 Antibody - Drug Profile 167
TLK-58747 - Drug Profile 168
TG-20 - Drug Profile 169
TH-302 - Drug Profile 170
darinaparsin - Drug Profile 177
(cytarabine + daunorubicin) - Drug Profile 179
SL-202 - Drug Profile 181
SL-201 - Drug Profile 182
HSV-TK - Drug Profile 183
HSV-TK - Drug Profile 185
SBC-201 - Drug Profile 187
SyB-0702 - Drug Profile 188
NOX-A12 - Drug Profile 189
MG-1 - Drug Profile 191
Kevetrin - Drug Profile 192
BP-100-1.02 - Drug Profile 195
sirolimus + [decitabine] - Drug Profile 196
ACTB-1011 - Drug Profile 197
DI-B4 - Drug Profile 198
tamibarotene - Drug Profile 199
tamibarotene - Drug Profile 201
lurbinectedin - Drug Profile 203
bardoxolone - Drug Profile 205
Combotox - Drug Profile 207
silmitasertib - Drug Profile 208
PU-27 - Drug Profile 210
exatecan mesylate - Drug Profile 211
AMG-900 - Drug Profile 213
ADI-PEG 20 - Drug Profile 215
Allogeneic Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes - Drug Profile 218
buparlisib - Drug Profile 220
palbociclib - Drug Profile 223
HGC-1 - Drug Profile 226
Autologous CD19 Specific T-cell Infusion + [cyclophosphamide] + [fludarabine phosphate] + Leukapheresis - Drug Profile 227
PHA-793887 - Drug Profile 228
GNKG-168 - Drug Profile 229
Minerval - Drug Profile 231
ofatumumab - Drug Profile 233
XIAP-cIAP - Drug Profile 237
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 238
DNA Methyltransferase Inhibitor - Drug Profile 240
F-14512 - Drug Profile 241
CA-18-C-3 - Drug Profile 242
MAT-303 - Drug Profile 243
LY-2090314 - Drug Profile 244
Vivia-009 - Drug Profile 245
DCC-2618 - Drug Profile 246
GO-203-2c - Drug Profile 247
BI-836826 - Drug Profile 248
PRI-724 - Drug Profile 249
CEP-37309 - Drug Profile 250
ABT-199 - Drug Profile 251
Leukothera - Drug Profile 254
Interleukin-1 Receptor Associated Protein Targeting Antibody - Drug Profile 255
MSM-112 - Drug Profile 257
PQR-311 - Drug Profile 258
TBI-0301 - Drug Profile 259
Lenaldekar - Drug Profile 260
IC-1208 - Drug Profile 261
IB-05202 - Drug Profile 262
Drug Targeting FAK, FLT3 And VEGFR3 - Drug Profile 263
OTX-015 - Drug Profile 265
BL-8040 - Drug Profile 266
ONO-4059 - Drug Profile 268
NCL49-1 - Drug Profile 269
metformin - Drug Profile 270
Anti-CD19-CAR-Transduced T Cells - Drug Profile 271
ATX-101 - Drug Profile 272
Fas Program - Drug Profile 273
Monoclonal Antibodies Targeting CD38 - Drug Profile 274
vincristine sulfate liposomal - Drug Profile 275
JRP-890 - Drug Profile 276
JRP-980 - Drug Profile 277
VS-1020 - Drug Profile 278
VS-1022 - Drug Profile 279
VS-1023 - Drug Profile 280
VS-1032 - Drug Profile 281
VS-1033 - Drug Profile 282
VS-1034 - Drug Profile 283
VS-1035 - Drug Profile 284
V-SlOlO - Drug Profile 285
Drug Targeting Menin - Drug Profile 286
BET Inhibitor Program - Drug Profile 287
Tumor-Derived Lymphocytes + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 288
EPZ-004777 - Drug Profile 289
Microtubule Binding Agents Programme - Drug Profile 290
Aloe-Emodin Glycoside - Drug Profile 291
IB-06F259 - Drug Profile 292
Genetically Modified T Cell - Drug Profile 293
Compound-22 - Drug Profile 294
interferon alfa-2b biosimilar - Drug Profile 295
Reprogrammed T Cells - Drug Profile 296
VAY-736 - Drug Profile 297
CG-203306 - Drug Profile 298
SNG-8033 - Drug Profile 299
XGP-210 - Drug Profile 300
XGP-215 - Drug Profile 301
Drug For Leukemia - Drug Profile 302
Triplebody 19x16x19 - Drug Profile 303
Triplebody 123x16x33 - Drug Profile 304
Drugs For Cancer - Drug Profile 305
CKBP-002 - Drug Profile 306
MSK-777 - Drug Profile 307
MSK-747 - Drug Profile 308
PMA-411R - Drug Profile 309
PV-327 - Drug Profile 310
Halistatin-1 - Drug Profile 311
Mabion CD20 - Drug Profile 312
Halistatin-2 - Drug Profile 314
filgrastim - Drug Profile 315
TAB-08 - Drug Profile 316
etomoxir - Drug Profile 318
KU-135 - Drug Profile 319
Carbazole Derivatives - Drug Profile 320
Laulimalide Derivatives - Drug Profile 321
Cell Therapy For Leukemia - Drug Profile 322
Epothilone Analogues - Drug Profile 323
Compound-8f - Drug Profile 324
Compound-11d - Drug Profile 325
Leukemias Therapeutics - Drug Profile Updates 326
Leukemias Therapeutics - Discontinued Products 407
Leukemias Therapeutics - Dormant Products 408
Leukemias - Product Development Milestones 414
Featured News and Press Releases 414
Appendix 425
Methodology 425
Coverage 425
Secondary Research 425
Primary Research 425
Expert Panel Validation 425
Contact Us 426
Disclaimer 426

List of Tables

Number of Products Under Development for Leukemias, H1 2013 23
Products under Development for Leukemias - Comparative Analysis, H1 2013 24
Number of Products under Development by Companies, H1 2013 26
Number of Products under Development by Companies, H1 2013 (Contd..1) 27
Number of Products under Development by Companies, H1 2013 (Contd..2) 28
Number of Products under Development by Companies, H1 2013 (Contd..3) 29
Number of Products under Development by Companies, H1 2013 (Contd..4) 30
Number of Products under Development by Companies, H1 2013 (Contd..5) 31
Number of Products under Development by Companies, H1 2013 (Contd..6) 32
Number of Products under Investigation by Universities/Institutes, H1 2013 34
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 35
Comparative Analysis by Late Stage Development, H1 2013 36
Comparative Analysis by Mid Clinical Stage Development, H1 2013 37
Comparative Analysis by Early Clinical Stage Development, H1 2013 38
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 39
Products under Development by Companies, H1 2013 40
Products under Development by Companies, H1 2013 (Contd..1) 41
Products under Development by Companies, H1 2013 (Contd..2) 42
Products under Development by Companies, H1 2013 (Contd..3) 43
Products under Development by Companies, H1 2013 (Contd..4) 44
Products under Development by Companies, H1 2013 (Contd..5) 45
Products under Development by Companies, H1 2013 (Contd..6) 46
Products under Development by Companies, H1 2013 (Contd..7) 47
Products under Investigation by Universities/Institutes, H1 2013 48
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 49
Boehringer Ingelheim GmbH, H1 2013 50
Amgen Inc., H1 2013 51
Eli Lilly and Company, H1 2013 52
Athersys, Inc., H1 2013 53
Seattle Genetics, Inc., H1 2013 55
MedImmune LLC, H1 2013 56
Daiichi Sankyo Company, Ltd, H1 2013 57
Emergent BioSolutions Inc., H1 2013 58
Gamida Cell Ltd., H1 2013 59
BioLineRx, Ltd., H1 2013 60
Amorfix Life Sciences Ltd., H1 2013 61
Bio-Path Holdings, Inc., H1 2013 62
ZIOPHARM Oncology, Inc., H1 2013 63
Novartis AG, H1 2013 64
Aphios Corporation, H1 2013 65
CK Life Sciences Int'l., (Holdings) Inc., H1 2013 66
Daewoong Pharmaceutical Co., Ltd., H1 2013 67
Genta Incorporated, H1 2013 68
GTC Biotherapeutics, Inc., H1 2013 69
Nippon Shinyaku Co., Ltd., H1 2013 70
Ono Pharmaceutical Co., Ltd., H1 2013 71
Pfizer Inc., H1 2013 72
SuperGen, Inc., H1 2013 73
Teva Pharmaceutical Industries Limited, H1 2013 74
Genmab A/S, H1 2013 75
Merck KGaA, H1 2013 76
Celldex Therapeutics, Inc., H1 2013 77
Marshall Edwards, Inc., H1 2013 78
MethylGene Inc, H1 2013 79
Northwest Biotherapeutics, Inc., H1 2013 80
Telik, Inc., H1 2013 81
Mundipharma International Limited, H1 2013 82
Pharmacyclics, Inc., H1 2013 83
Cytomedix, Inc., H1 2013 84
Array BioPharma Inc., H1 2013 85
Threshold Pharmaceuticals, Inc., H1 2013 86
CrystalGenomics, Inc., H1 2013 87
Sareum Holdings plc, H1 2013 88
MetrioPharm AG, H1 2013 89
SymBio Pharmaceuticals Limited, H1 2013 90
Abiogen Pharma S.p.A., H1 2013 91
Multimmune GmbH, H1 2013 92
Nerviano Medical Sciences S.r.l., H1 2013 93
ViroStatics, srl, H1 2013 94
MAT Biopharma, H1 2013 95
Celator Pharmaceuticals, Inc., H1 2013 96
Hawthorn Pharmaceuticals, Inc., H1 2013 97
ACT Biotech, Inc., H1 2013 98
Constellation Pharmaceuticals, Inc., H1 2013 99
Deciphera Pharmaceuticals, LLC, H1 2013 100
MSM Protein Technologies, Inc., H1 2013 101
Reata Pharmaceuticals, Inc., H1 2013 102
Stemline Therapeutics, Inc., H1 2013 103
Synageva BioPharma Corp., H1 2013 104
MolMed S.p.A., H1 2013 105
NOXXON Pharma AG, H1 2013 106
Morphogenesis, Inc., H1 2013 107
SBI Biotech Co., Ltd., H1 2013 108
Tragara Pharmaceuticals, Inc., H1 2013 109
Cellceutix Corporation, H1 2013 110
PharmaMar, S.A., H1 2013 111
Cylene Pharmaceuticals, Inc., H1 2013 112
Lipopharma, H1 2013 113
Keystone Nano, Inc., H1 2013 114
Toko Pharmaceutical Industries Co., Ltd., H1 2013 115
Cancer Therapeutics CRC Pty Ltd, H1 2013 116
EpiZyme, Inc., H1 2013 117
Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd., H1 2013 118
iCeutica, Inc., H1 2013 119
Polaris Group, H1 2013 120
XBiotech USA, Inc., H1 2013 121
Wellstat Biologics Corporation, H1 2013 122
Advancell, H1 2013 124
Assessment by Monotherapy Products, H1 2013 125
Assessment by Combination Products, H1 2013 126
Assessment by Stage and Route of Administration, H1 2013 128
Assessment by Stage and Molecule Type, H1 2013 131
Leukemias Therapeutics - Drug Profile Updates 336
Leukemias Therapeutics - Discontinued Products 417
Leukemias Therapeutics - Dormant Products 418
Leukemias Therapeutics - Dormant Products (Contd..1) 419
Leukemias Therapeutics - Dormant Products (Contd..2) 420
Leukemias Therapeutics - Dormant Products (Contd..3) 421
Leukemias Therapeutics - Dormant Products (Contd..4) 422
Leukemias Therapeutics - Dormant Products (Contd..5) 423

List of Figures

Number of Products under Development for Leukemias, H1 2013 23
Products under Development for Leukemias - Comparative Analysis, H1 2013 24
Products under Development by Companies, H1 2013 25
Products under Investigation by Universities/Institutes, H1 2013 33
Late Stage Products, H1 2013 36
Mid Clinical Stage Products, H1 2013 37
Early Clinical Stage Products, H1 2013 38
Discovery and Pre-Clinical Stage Products, H1 2013 39
Assessment by Monotherapy Products, H1 2013 125
Assessment by Combination Products, H1 2013 126
Assessment by Route of Administration, H1 2013 127
Assessment by Stage and Route of Administration, H1 2013 128
Assessment by Molecule Type, H1 2013 129
Assessment by Stage and Molecule Type, H1 2013 130

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Clare

+1 339 368 6001

Purchase Reports From Reputable Market Research Publishers

Aarti Drugs Ltd. (AARTIDRUGS) - Financial and Strategic SWOT Analysis Review

Aarti Drugs Ltd. (AARTIDRUGS) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • April 2015
  • by Global Data

Summary Aarti Drugs Ltd. (ADL) is a pharmaceutical company. It carries out the development and manufacture of generic bulk actives, advanced intermediates and specialty chemicals. ADL’s product portfolio ...

Mangalam Drugs and Organics Limited (MANGALAM) - Financial and Strategic SWOT Analysis Review

Mangalam Drugs and Organics Limited (MANGALAM) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • April 2015
  • by Global Data

Summary Mangalam Drugs and Organics Limited (Mangalam) is a chemical products manufacturing company. The company manufactures chemicals such as API, perfumery chemicals, disperse dye intermediates. It ...

Kilitch Drugs (India) Ltd. (KILITCH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Kilitch Drugs (India) Ltd. (KILITCH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • April 2015
  • by Global Data

Summary Kilitch Drugs (India) Ltd. (Kilitch) is a pharmaceutical company. The company manufactures and markets antibacterial parenteral formulations and other pharmaceutical products. Its products include ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.